Glycoconjugate vaccines to prevent group B streptococcal infections

Group B Streptococcus (GBS) is an opportunistic pathogen of humans. At-risk populations include neonates born to colonised mothers, peripartum women, diabetics, and the elderly with underlying illnesses. Vaccines to prevent GBS disease have been developed by coupling purified capsular polysaccharide (CPS) antigen of GBS with an immunogenic protein carrier. Glycoconjugate vaccines against all nine currently identified GBS serotypes have been synthesised and shown to be immunogenic in mice, rabbits and baboons in preclinical trials. Healthy adults have safely received conjugate vaccines prepared with GBS types Ia, Ib, II, III, and V CPSs in Phase I and II clinical trials. These vaccines elicited CPS-specific antibody that opsonised GBS for in vitro killing by human peripheral blood leukocytes in the presence of complement. Results from these preclinical and clinical studies strongly suggest that GBS conjugate vaccines will be effective in preventing diseases caused by GBS.

[1]  D. Kasper,et al.  Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. , 2003, The Journal of infectious diseases.

[2]  B. Trollfors,et al.  Invasive group B streptococcal infections in Sweden: incidence, predisposing factors and prognosis. , 2003, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[3]  R. Vuento,et al.  Invasive Group B Streptococcal Infections in Finland: A Population-based Study , 2003, Emerging infectious diseases.

[4]  R. Rappuoli,et al.  Two years into reverse vaccinology. , 2003, Vaccine.

[5]  Rino Rappuoli,et al.  Reverse vaccinology. , 2000, Current opinion in microbiology.

[6]  Carmen Buchrieser,et al.  Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease , 2002, Molecular microbiology.

[7]  H. Tettelin,et al.  Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays , 2002, Nature Biotechnology.

[8]  Ian T. Paulsen,et al.  Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  L. Madoff,et al.  Vaccines to prevent neonatal GBS infection. , 2002, Seminars in neonatology : SN.

[10]  Y. Abdulrazzaq,et al.  Group B streptococcal serotype distribution of isolates from colonized pregnant women at the time of delivery in United Arab Emirates. , 2002, The Journal of infection.

[11]  D. Kasper,et al.  Conjugate vaccines against group B Streptococcus types IV and VII. , 2002, The Journal of infectious diseases.

[12]  L. Meyn,et al.  Association of sexual activity with colonization and vaginal acquisition of group B Streptococcus in nonpregnant women. , 2002, American journal of epidemiology.

[13]  D. Kasper,et al.  Type III Group B Streptococcal Polysaccharide Induces Antibodies That Cross-React with Streptococcus pneumoniae Type 14 , 2002, Infection and Immunity.

[14]  M. D. de Almeida,et al.  A survey of the incidence of neonatal sepsis by group B Streptococcus during a decade in a Brazilian maternity hospital. , 2002, The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.

[15]  D. Kasper,et al.  Quantitative determination of immunoglobulin G specific for group B streptococcal beta C protein in human maternal serum. , 2002, The Journal of infectious diseases.

[16]  New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Final rule. , 2002, Federal register.

[17]  D. Kasper,et al.  Effects of Alum Adjuvant or a Booster Dose on Immunogenicity during Clinical Trials of Group B Streptococcal Type III Conjugate Vaccines , 2001, Infection and Immunity.

[18]  L. Paoletti,et al.  Use of a dynamic in vitro attachment and invasion system (DIVAS) to determine influence of growth rate on invasion of respiratory epithelial cells by group B Streptococcus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  P. Paradiso,et al.  Maternal immunization: the influence of liability issues on vaccine development. , 2001, Vaccine.

[20]  A. Schuchat.  Group B streptococcal disease: from trials and tribulations to triumph and trepidation. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  L. Nyström,et al.  Intrauterine infection may be a major cause of stillbirth in Sweden , 2001, Acta obstetricia et gynecologica Scandinavica.

[22]  J. Holmgren,et al.  Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate. , 2001, Vaccine.

[23]  A. Schuchat,et al.  Invasive group B streptococcal disease in Maryland nursing home residents. , 2001, The Journal of infectious diseases.

[24]  L. Paoletti.  Potency of clinical group B streptococcal conjugate vaccines. , 2001, Vaccine.

[25]  S. Lockhart,et al.  Efficacy of a pneumococcal conjugate vaccine against acute otitis media. , 2001, The New England journal of medicine.

[26]  M. Avison,et al.  Interscience Conference on Antimicrobial Agents and Chemotherapy , 2001 .

[27]  D. Kasper,et al.  Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women. , 2000, The Journal of infectious diseases.

[28]  I. Charlebois,et al.  Identification of Group B Streptococcal Sip Protein, Which Elicits Cross-Protective Immunity , 2000, Infection and Immunity.

[29]  J. Holmgren,et al.  Systemic and Mucosal Immune Responses in Mice after Mucosal Immunization with Group B Streptococcus Type III Capsular Polysaccharide-Cholera Toxin B Subunit Conjugate Vaccine , 2000, Infection and Immunity.

[30]  G. Tyrrell,et al.  Invasive disease due to group B streptococcal infection in adults: results from a Canadian, population-based, active laboratory surveillance study--1996. Sentinel Health Unit Surveillance System Site Coordinators. , 2000, The Journal of infectious diseases.

[31]  R. Platt,et al.  Invasive disease due to group B Streptococcus in pregnant women and neonates from diverse population groups. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  D. Kasper,et al.  Maternal antibody transfer in baboons and mice vaccinated with a group B streptococcal polysaccharide conjugate. , 2000, The Journal of infectious diseases.

[33]  A. Schuchat,et al.  Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. , 2000, The New England journal of medicine.

[34]  B. Stoll,et al.  Risk Factors and Opportunities for Prevention of Early-Onset Neonatal Sepsis: A Multicenter Case-Control Study , 1999, Pediatrics.

[35]  H. McDonald,et al.  Intrauterine infection and spontaneous midgestation abortion: is the spectrum of microorganisms similar to that in preterm labor? , 2000, Infectious diseases in obstetrics and gynecology.

[36]  D. Kasper,et al.  Cognate Stimulatory B-Cell–T-Cell Interactions Are Critical for T-Cell Help Recruited by Glycoconjugate Vaccines , 1999, Infection and Immunity.

[37]  N. Thomas,et al.  Neonatal Group B Streptococcal bacteraemia in India: ten years’experience , 1999, Acta paediatrica.

[38]  D. Kasper,et al.  Synthesis and preclinical evaluation of glycoconjugate vaccines against group B Streptococcus types VI and VIII. , 1999, The Journal of infectious diseases.

[39]  D. Kasper,et al.  Alpha C Protein as a Carrier for Type III Capsular Polysaccharide and as a Protective Protein in Group B Streptococcal Vaccines , 1999, Infection and Immunity.

[40]  M. Lipsitch.  Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. , 1999, Emerging infectious diseases.

[41]  D. Kasper,et al.  Serotypes VI and VIII predominate among group B streptococci isolated from pregnant Japanese women. , 1999, The Journal of infectious diseases.

[42]  G. Lindahl,et al.  Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine. , 1999, Vaccine.

[43]  D. Kasper,et al.  Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. , 1999, The Journal of infectious diseases.

[44]  L. Paoletti,et al.  Vaccines: From Concept to Clinic A Guide to the Development and Clinical Testing of Vaccines for Human Use , 1998 .

[45]  D. Kasper,et al.  Therapeutic potential of human antisera to group B streptococcal glycoconjugate vaccines in neonatal mice. , 1997, The Journal of infectious diseases.

[46]  D. Kasper,et al.  Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. , 1996, The Journal of clinical investigation.

[47]  D. Kasper,et al.  Immunogenicity of group B Streptococcus type III polysaccharide-tetanus toxoid vaccine in baboons , 1996, Infection and immunity.

[48]  D. Kasper,et al.  Quantitative determination of antibodies to type III group B streptococcal polysaccharide. , 1996, The Journal of infectious diseases.

[49]  D. Isaacs,et al.  Early‐onset group B streptococcal infections in Aboriginal and non‐Aboriginal infants , 1995, The Medical journal of Australia.

[50]  D. Kasper,et al.  Immunogenicity and protective activity in animals of a type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. , 1995, The Journal of infectious diseases.

[51]  A. Schuchat.  Group B streptococcal disease in newborns: a global perspective on prevention. , 1995, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[52]  D. Kasper,et al.  Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine , 1994, Infection and immunity.

[53]  D. Kasper,et al.  Maternal immunization of mice with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective antibody to multiple serotypes. , 1994, The Journal of clinical investigation.

[54]  D. Kasper,et al.  Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine , 1993, Infection and immunity.

[55]  P. Mäkelä,et al.  Vaccination with Haemophilus influenzae type b meningococcal protein conjugate vaccine reduces oropharyngeal carriage of Haemophilus influenzae type b among American Indian children , 1993, The Pediatric infectious disease journal.

[56]  B. Plikaytis,et al.  Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae type b vaccines , 1993, The Pediatric infectious disease journal.

[57]  A. Schuchat,et al.  A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. , 1993, The New England journal of medicine.

[58]  G. Lindahl,et al.  Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections , 1993, The Journal of experimental medicine.

[59]  D. Kasper,et al.  Group B Streptococcus type II polysaccharide-tetanus toxoid conjugate vaccine , 1992, Infection and immunity.

[60]  D. Kasper,et al.  Neonatal mouse model of group B streptococcal infection. , 1992, The Journal of infectious diseases.

[61]  L. Givner.  Human immunoglobulins for intravenous use: comparison of available preparations for group B streptococcal antibody levels, opsonic activity, and efficacy in animal models. , 1990, Pediatrics.

[62]  D. Kasper,et al.  Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. , 1990, The Journal of clinical investigation.

[63]  D. Kasper,et al.  An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus. , 1990, The Journal of biological chemistry.

[64]  J. Shiloach,et al.  Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid , 1990, Infection and immunity.

[65]  D. Kasper,et al.  Group B streptococcal vaccines. , 1985, Reviews of infectious diseases.

[66]  J. Motlová,et al.  Worldwide distribution of two new serotypes of group B streptococci: type IV and provisional type V , 1985, Journal of clinical microbiology.

[67]  R. Horton,et al.  From the National Institute of Allergy and Infectious Diseases. Summary of the National Institutes of Health workshop on group B streptococcal infection. , 1983, The Journal of infectious diseases.

[68]  D. Kasper,et al.  Immunochemical analysis and immunogenicity of the type II group B streptococcal capsular polysaccharide. , 1983, The Journal of clinical investigation.

[69]  J. Klein,et al.  Infectious Diseases of the Fetus and Newborn Infant , 1983 .

[70]  T. Eisenstein,et al.  Quantitative determination in human sera of vaccine-induced antibody to type-specific polysaccharides of group B streptococci using an enzyme-linked immunosorbent assay. , 1983, The Journal of infectious diseases.

[71]  K. Boyer,et al.  Group B streptococcal infections. , 2002, Pediatrics in review.

[72]  D. Kasper,et al.  Immunogenicity of polysaccharides from type III, group B Streptococcus. , 1978, The Journal of clinical investigation.

[73]  D. Kasper,et al.  Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. , 1977, Journal of immunology.

[74]  P. Wright,et al.  From the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Center for Disease Control, and the Bureau of Biologics of the Food and Drug Administration. Summary of clinical trials of influenza vaccines--II. , 1976, The Journal of infectious diseases.

[75]  D. Haynes.  Neonatal sepsis and other infections due to group B beta-hemolytic streptococci , 1965 .

[76]  M. Finland,et al.  NEONATAL SEPSIS AND OTHER INFECTIONS DUE TO GROUP B BETA-HEMOLYTIC STREPTOCOCCI. , 1964, The New England journal of medicine.